Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Filings indexed 1,019 across all filing types
Latest filing 2018-05-23 Regulatory Filings
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease amendment, and the creation of a direct financial obligation. There are no financial statements or detailed financial performance data presented, only a description of the lease amendment and related obligations. The document is about a specific event and does not constitute an annual or quarterly report, earnings release, or other detailed financial report. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2018-05-23 English
FORM 4 SUBMISSION
Director's Dealing
2018-05-16 English
FORM 3 SUBMISSION
Director's Dealing
2018-05-16 English
FORM 4 SUBMISSION
Director's Dealing
2018-05-14 English
DEF 14A
Proxy Solicitation & Information Statement
2018-05-11 English
FORM 10-Q
Interim / Quarterly Report 9M 2018
2018-05-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.